ArticleOncogene2014
SPROUTY2 is a β-catenin and FOXO3a target gene indicative of poor prognosis in colon cancer.
Article in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Dual Roles of CCN5/WISP2 in Cytosol and Secretome for Maintaining Muscle Homeostasis and Preventing Sarcopenia.Journal of cachexia, sarcopenia and muscle · 2026Article
- The future of Forkhead box O transcription factors.The Biochemical journal · 2026Review
- FOXO3a-interacting proteins' involvement in cancer: a review.Molecular biology reports · 2024Review
- API-2-Induced Cell Migration Is Overcome by Small Molecular Approaches Inhibiting β-Catenin.Current issues in molecular biology · 2022Article
- Article
- Review
- Loss of Spry1 reduces growth of BRAFCell death & disease · 2020Article
- Wnt signaling in orofacial clefts: crosstalk, pathogenesis and models.Disease models & mechanisms · 2019Review
- Sprouty2 correlates with favorable prognosis of gastric adenocarcinoma via suppressing FGFR2-induced ERK phosphorylation and cancer progression.Oncotarget · 2017Article
- Hypoxia inducible factors regulate the transcription of the sprouty2 gene and expression of the sprouty2 protein.PloS one · 2017Article
- Atypical role of sprouty in p21 dependent inhibition of cell proliferation in colorectal cancer.Molecular carcinogenesis · 2016Article
- Atypical role of sprouty in colorectal cancer: sprouty repression inhibits epithelial-mesenchymal transition.Oncogene · 2016Article
- SPROUTY-2 represses the epithelial phenotype of colon carcinoma cells via upregulation of ZEB1 mediated by ETS1 and miR-200/miR-150.Oncogene · 2016Article
- Comparative Microarray Analysis of Proliferating and Differentiating Murine ENS Progenitor Cells.Stem cells international · 2016Article
- Sprouty2 Drives Drug Resistance and Proliferation in Glioblastoma.Molecular cancer research : MCR · 2015Article
- Impact of Nutrition on Non-Coding RNA Epigenetics in Breast and Gynecological Cancer.Frontiers in nutrition · 2015Review
- β-catenin enhances odontoblastic differentiation of dental pulp cells through activation of Runx2.PloS one · 2014Article
- Forkhead box transcription factors in cancer initiation, progression and chemotherapeutic drug response.Frontiers in oncology · 2014Article
- FOXO3a: A Potential Target in Prostate Cancer.Austin journal of urologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SPROUTY2 (SPRY2) is an intracellular regulator of receptor tyrosine kinase signaling involved in cell growth, differentiation and tumorigenesis. Here, we show that SPRY2 is a target gene of the Wnt/β-catenin pathway that is abnormally activated in more than 90% of colon carcinomas. In human colon cancer cells, SPRY2 expression is induced by β-catenin in co-operation with the transcription factor FOXO3a instead of lymphoid enhancer factor/T-cell factor proteins. We found binding of β-catenin to the SPRY2 promoter at FOXO3a response elements. In vivo, cells marked by nuclear β-catenin and FOXO3a express SPRY2 in proliferative epithelial tissues, such as intestinal mucosa and epidermis. Consistently, inducible β-catenin deletion in mice reduced Spry2 expression in the small intestine. Moreover, SPRY2 protein expression correlated with nuclear β-catenin and FOXO3a colocalization in human colon carcinomas. Importantly, the amount of SPRY2 protein correlated with shorter overall survival of colon cancer patients. Our data reveal SPRY2 as a novel Wnt/β-catenin and FOXO3a target gene indicative of poor prognosis in colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.